Pharma and biotech firms not using ‘green chemistry’ to make their products incur higher costs and risk losing market share according to Piramal.
DSM may have narrowed the focus of its pharmaceutical business, but the supplier is still trying to win drug industry customers at a trade show in Spain.
A BASF expert is calling for an independent review body for new excipients to reassure wary drugmakers of their quality.
The cost of outsourcing is far more than simply the price per kilogram of an API says Hovione, which is expanding a plant in New Jersey.
Charles River Laboratories has inked a number of deals across its discovery service business.
Symbiosis has decided to increase manufacturing capacity at its sterile injectable drugs facility in response to increased demand.